BioCentury | Nov 16, 2015
Emerging Company Profile

Bridge to POC

BRIM Biotechnology Inc. has assembled a team of translational science veterans to fill what it sees as a gap in Taiwanese drug development capabilities. The company plans to bring in preclinical projects with global commercialization...
BioCentury | Jun 16, 2014
Finance

Biotech rating scheme

Claravant Analytics LLC is aiming to change the biotech investment ecosystem by leveling the playing field for public investors that don't have access to confidential information. The firm plans to serve as a third-party intermediary...
BC Week In Review | Sep 30, 2013
Clinical News

Simponi golimumab regulatory update

The European Commission approved Simponi golimumab from Johnson & Johnson for the treatment of moderately to severely active ulcerative colitis (UC) in adult patients who have had an inadequate response to conventional therapy or who...
BioCentury | Aug 12, 2013
Finance

Abiding no more

Abiding no more Unable to raise venture money when it spun out of service play Epitomics Inc. in 2010, Apexigen Inc. was able to work for three years using $2 million in seed funding plus...
BC Week In Review | Aug 5, 2013
Clinical News

Simponi golimumab regulatory update

EMA's CHMP issued a positive opinion recommending expanding the label of Simponi golimumab from Johnson & Johnson to include treatment of moderately to severely active ulcerative colitis (UC) in adult patients who have had an...
BC Week In Review | May 20, 2013
Clinical News

Simponi golimumab regulatory update

FDA approved an sBLA from Johnson & Johnson for subcutaneous Simponi golimumab to treat moderately to severely active ulcerative colitis (UC) in adults who had an inadequate response to conventional therapy. In July, J&J submitted...
BC Week In Review | May 20, 2013
Company News

Aveo Pharmaceuticals, J&J deal

Aveo disclosed in a 10-Q filing that Johnson & Johnson's Janssen Biotech Inc. (formerly Centocor Ortho Biotech Inc.) unit terminated a 2011 deal to develop and commercialize mAbs for cancer on Dec. 6, 2012. Under...
BC Week In Review | Jul 23, 2012
Clinical News

Simponi golimumab regulatory update

Johnson & Johnson submitted an sBLA to FDA and a Type II variation to EMA seeking to expand the label of subcutaneous Simponi golimumab to include treatment of moderately to severely active ulcerative colitis in...
BC Innovations | Jun 28, 2012
Targets & Mechanisms

Fragmentary progress in endometriosis

A team from the Baylor College of Medicine has treated endometriosis in mice by blocking a pathway that produces a fragment of nuclear receptor coactivator 1 in endometrial tissue. 1 Now, small molecule inhibitors are...
BC Week In Review | Jun 18, 2012
Clinical News

Simponi golimumab: Phase III data

The double-blind, international Phase III GO-FURTHER trial in 592 patients with active moderate to severe RA despite methotrexate treatment showed that 2 mg/kg IV Simponi given at weeks 0 and 4 and then every 8...
Items per page:
1 - 10 of 847
BioCentury | Nov 16, 2015
Emerging Company Profile

Bridge to POC

BRIM Biotechnology Inc. has assembled a team of translational science veterans to fill what it sees as a gap in Taiwanese drug development capabilities. The company plans to bring in preclinical projects with global commercialization...
BioCentury | Jun 16, 2014
Finance

Biotech rating scheme

Claravant Analytics LLC is aiming to change the biotech investment ecosystem by leveling the playing field for public investors that don't have access to confidential information. The firm plans to serve as a third-party intermediary...
BC Week In Review | Sep 30, 2013
Clinical News

Simponi golimumab regulatory update

The European Commission approved Simponi golimumab from Johnson & Johnson for the treatment of moderately to severely active ulcerative colitis (UC) in adult patients who have had an inadequate response to conventional therapy or who...
BioCentury | Aug 12, 2013
Finance

Abiding no more

Abiding no more Unable to raise venture money when it spun out of service play Epitomics Inc. in 2010, Apexigen Inc. was able to work for three years using $2 million in seed funding plus...
BC Week In Review | Aug 5, 2013
Clinical News

Simponi golimumab regulatory update

EMA's CHMP issued a positive opinion recommending expanding the label of Simponi golimumab from Johnson & Johnson to include treatment of moderately to severely active ulcerative colitis (UC) in adult patients who have had an...
BC Week In Review | May 20, 2013
Clinical News

Simponi golimumab regulatory update

FDA approved an sBLA from Johnson & Johnson for subcutaneous Simponi golimumab to treat moderately to severely active ulcerative colitis (UC) in adults who had an inadequate response to conventional therapy. In July, J&J submitted...
BC Week In Review | May 20, 2013
Company News

Aveo Pharmaceuticals, J&J deal

Aveo disclosed in a 10-Q filing that Johnson & Johnson's Janssen Biotech Inc. (formerly Centocor Ortho Biotech Inc.) unit terminated a 2011 deal to develop and commercialize mAbs for cancer on Dec. 6, 2012. Under...
BC Week In Review | Jul 23, 2012
Clinical News

Simponi golimumab regulatory update

Johnson & Johnson submitted an sBLA to FDA and a Type II variation to EMA seeking to expand the label of subcutaneous Simponi golimumab to include treatment of moderately to severely active ulcerative colitis in...
BC Innovations | Jun 28, 2012
Targets & Mechanisms

Fragmentary progress in endometriosis

A team from the Baylor College of Medicine has treated endometriosis in mice by blocking a pathway that produces a fragment of nuclear receptor coactivator 1 in endometrial tissue. 1 Now, small molecule inhibitors are...
BC Week In Review | Jun 18, 2012
Clinical News

Simponi golimumab: Phase III data

The double-blind, international Phase III GO-FURTHER trial in 592 patients with active moderate to severe RA despite methotrexate treatment showed that 2 mg/kg IV Simponi given at weeks 0 and 4 and then every 8...
Items per page:
1 - 10 of 847